NCT02594865View on ClinicalTrials.gov

The Glycaemic Effects of Glucerna® in Critically Ill Patients.

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Disorder of Glucose Regulation
Interventions
DIETARY_SUPPLEMENT

Glucerna

Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.

DIETARY_SUPPLEMENT

Fresubin

Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.

Trial Locations (1)

1091 AC

Onze Lieve Vrouwe Gasthuis, Amsterdam

All Listed Sponsors
collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

lead

PHJ van der Voort

OTHER

NCT02594865 - The Glycaemic Effects of Glucerna® in Critically Ill Patients. | Biotech Hunter | Biotech Hunter